key: cord-0831142-mnwjs1q5 authors: Lyu, Aihua; Jin, Tengchuan; Wang, Shanshan; Huang, Xiaoxue; Zeng, Weihong; Yang, Rui; Cui, Hua title: Automatic label-free immunoassay with high sensitivity for rapid detection of SARS-CoV-2 nucleocapsid protein based on chemiluminescent magnetic beads date: 2021-12-15 journal: Sens Actuators B Chem DOI: 10.1016/j.snb.2021.130739 sha: e3ac6be97d4cd202342db8be532e743ac4097067 doc_id: 831142 cord_uid: mnwjs1q5 Accurate and efficient early diagnosis is crucial for the control of COVID-19 pandemic. However, methods that can balance sensitivity, high throughput, detection speed and automation simultaneously are still scarce. Here, we report an automatic label-free chemiluminescence immunoassay (CLIA) for rapid SARS-CoV-2 nucleocapsid protein (NP) detection with high sensitivity and throughput. N-(4-aminobutyl)-N-ethylisoluminol and Co(2+) dual-functionalized chemiluminescent magnetic beads (dfCL-MB) were first applied to the detection of protein by a novel and simple strategy. Sulphydryl polyethylene glycol was coated on the surface of dfCL-MB so as to assemble dfCL-MB and antibody conjugated gold nanoparticles through Au-S bond. Considering the high-risk application scenarios, the immunosensor was integrated with an automatic chemiluminescence analyzer so that the whole testing procedure could be carried out automatically without manual operation. A linear correlation between CL intensities and the logarithm of NP concentration was obtained in the range of 0.1–10,000 pg/mL with a detection limit of 21 fg/mL. The whole process cost 25 min and the sample compartment can bear 24 samples simultaneously. The spiked human serum samples and serum samples from COVID-19 patients were determined with satisfactory recoveries of 91.1–109.4%, suggesting that the proposed label-free CLIA is of great potential for SARS-CoV-2 NP detection in practice. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) [1] has become a major public health concern all over the world. Until February 2021, more than 2.49 million people have died of COVID-19 and the number is still increasing rapidly [2] . Clinical research indicates that most infected people develop respiratory symptoms in 2 to14 days after exposure (namely, incubation period) [3, 4] . To make matters worse, asymptomatic carriers and patients in the incubation period still can transmit the virus effectively [5, 6] . The high infectivity and the indefinite incubation period of SARS-CoV-2 make the pandemic situation even serious. Therefore, accurate and efficient early diagnosis is crucial for patient management and outbreak control. Pathogenic nucleic acid testing based on quantitative real time polymerase chain reaction (qRT-PCR) and serological antibody testing are the main laboratory methods for clinical diagnosis of COVID-19 currently [7, 8] . However, qRT-PCR requires skilled technicians, expensive reagents and complicated time-consuming amplification steps. A considerable amount of nucleic acid loss is caused in the complex extraction steps, which may lead to a false negative result. Moreover, the high cost of mass population screening by qRT-PCR has resulted in great financial pressure even for well-funded health care systems. Likewise, antibody testing also has some shortcomings. The most important one is that the positive rate of the serum virus-specific IgM and IgG antibody is low when the sampling time is within one week of symptom onset [3, 9] , not to mention that of asymptomatic carriers. This means antibody testing is unsuitable for early screening and can only be used as a complement to pathogenic testing [9] . The structural proteins of SARS-CoV-2, such J o u r n a l P r e -p r o o f as spike protein (SP) and nucleocapsid protein (NP), as another component of the pathogen, has been declared feasible for the diagnosis of COVID-19 by World Health Organization (WHO) [10] . Both NP and SP have high antigenicities [11, 12] . However, it has been reported that N gene is more conserved and stable than S gene and has fewer mutations over time [11, [13] [14] [15] . Therefore, NP is potentially a better target for a stable and effective SARS-CoV-2 antigen detection method. Several works for SARS-CoV-2 NP detection have been published. For example, lateral flow immunoassay (LFA) for SARS-CoV-2 NP [16] [17] [18] has gained much attention due to its low cost and portability. Hess et.al. [19] developed a parallel reaction monitoring mass spectrometry assay for detection of SARS-CoV-2 SP and NP, which provided a detection limit of ∼200 aM. Zhang's group [20] reported an aptamer-assisted proximity ligation assay for COVID-19 diagnosis with a NP detection limit of 37.5 pg mL -1 . These methods have solved different problems that we are facing in COVID-19 diagnosis, respectively. However, there are still some limitations. LFA is semiquantitative method and the sensitivity is sacrificed, which is an essential trait to patients in the early stage because of the low viral load [5] . The other methods have good performance in sensitivity, but they need hours to complete the whole test and complex manual operation are applied in various degrees, which makes these methods both labor-intensive and time-consuming. Methods that can balance sensitivity, high throughput, detection speed and automation simultaneously for the detection of SARS-CoV-2 NP are still scarce. In recent years, great attention has been paid to chemiluminescence immunoassays (CLIAs) for disease biomarkers in practical in vitro diagnosis (IVD) due to inherent advantages such as high sensitivity, wide linear range, short detection time and simple devices [21] [22] [23] [24] [25] . While most of current CLIAs used in IVD are mainly labeling-based sandwich method [26, 27] . Furthermore, CL substrate is usually added in liquid phase, which is another error-causing factor. Label-free CLIA [28] [29] [30] based on CL intensity change initiated by the specific interaction between recognition element modified on CL functionalized nanomaterials and target have drawn increasing research interests. They are time-saving, low-cost, and simple, avoiding tedious labeling procedures. N-(4-aminobutyl)-N-ethylisoluminol (ABEI) and cobalt ion dual-functionalized chemiluminescent magnetic beads (dfCL-MB) as powerful interfaces are very attractive for the construction of label-free CLIA due to their rapid and simple separation from matrix, high feasibility of automation and low energy J o u r n a l P r e -p r o o f requirement. However, the application of dfCL-MB is restricted to the detection of small molecule [31, 32] . Label-free CLIA for protein biomarkers based on dfCL-MB has rarely been reported. In this work, we developed an automatic label-free CLIA with high sensitivity for the rapid detection of SARS-CoV-2 NP. dfCL-MB were taken as the carrier of CL reagent ABEI and catalyst Co 2+ as well as the interface of the label-free CLIA. As the carboxyl group of MB was occupied by ABEI and Co 2+ , it was hard to immobilize antibody directly. Therefore, citrate reduced gold nanoparticles were used to conjugate NP antibody (AuNP-Ab) due to its excellent protein affinity and stability. Moreover, polyethylene glycol with a sulfhydryl group at the end (SH-PEG) was chosen as the bridging molecule between AuNP-Ab and dfCL-MB because PEG as a polymer could be modified on dfCL-MB through non-covalent interactions and AuNP-Ab could be well conjugated via Au-S bond. Finally, the label-free immunosensor was obtained when the non-specific sites were blocked by BSA. It was found that NP had a negative impact on the CL intensity of the as-assembled immunosensor. Under these circumstances, a label-free CLIA was established. Considering the high-risk application scenarios, the label-free CLIA was integrated with an automatic CL analyzer so that the whole testing procedure could be carried out automatically without manual operation. The assembly process was characterized by CL, XPS, TEM, STEM, etc. After the CL measurement conditions were optimized, analytical performance and selectivity of the label-free CLIA were evaluated. Ultimately, the spiked human serum samples with NP and serum samples of COVID-19 patients were employed to investigate the applicability of the immunosensor in practical COVID-19 diagnosis. Trisodium citrate (Na 3 Cit), sodium chloride (NaCl), sodium hydroxide (NaOH), was employed to produce ultrapure water which was used throughout the experiment. TEM images were recorded on an electronic microscope (JEM-2010, Japan). A high resolution electronic microscope (Talos F200X, USA) were used to collect HAADF images and EDS mapping images. XPS (Al Kα radiation as the X-ray source) was performed on an electronic spectrometer (ESCALAB 250Xi, USA). Inductively coupled plasma mass spectrometry (ICP-MS) measurements were carried out on a mass spectrometry (PlasmaQuad3, USA). UV-vis absorption spectra were conducted on an UV-vis spectrophotometer (Agilent 8453, USA). Magnetization curves were performed on a magnetic measurement system (MPMS3, USA). The zeta potential was detected using a zeta potential analyzer (90Plus PALS, USA). The centrifugation process was carried out on a high-speed refrigerated centrifuge (TGL-16M, China). The pH of solutions used in this work was controlled by a pH meter (FE-28 standard, China). The citrate reduced gold nanoparticles (cit-AuNPs) were synthesized on a constant temperature heating magnetic stirrer (DF-101S, China). All shaking processes were performed on a DNA rotary mixer (DH-II, China). First of all, ABEI and Co 2+ dual-functionalized CL magnetic beads (dfCL-MB) were prepared according to a previous work of our group [32] with some modifications as shown in S1. Secondly, 0. The assembly strategy of the label-free CL immunosensor is shown in Scheme 1. First of all, ABEI and Co 2+ dual-functionalized CL magnetic beads (dfCL-MB) were prepared according to our previous work with some modifications [32] . To monitor the assembly process, a series of characterizations were conducted. Figure 1A -D display typical TEM images of MB surface during the assembly process. The commercial MBs were highly uniform microspheres with an average diameter of 2.17 ± 0.05 μm ( Figure S1 ). After functionalized with ABEI and Co 2+ , there was no obvious change in morphology ( Figure 1A ). The surface of PEG/dfCL-MB ( Figure 1B ) showed no obvious difference compared with that of dfCL-MB ( Figure 1A ) due to the low contrast of PEG under TEM. The successful coating of PEG was reflected in XPS results. As shown in Figure S4 PEG/dfCL-MB and cit-AuNPs, resulting in a decrease in CL intensity [34] . Furthermore, sulphydryl group as a common group in antibodies may also exist in NP antibody, leading to a decrease in CL intensity. Moreover, the peak drop of Figure 2B , the CL intensities obtained by Kaeser 1000 showed the consistent regulation with that obtained by Centro LB 960, indicating the high feasibility of integrating the as-assembled immunosensor with Kaeser 1000. Compared with MB, the saturation magnetization of BSA/AuNP-Ab/PEG/dfCL-MB decreased by 1.4 emu/g, which was ascribed to the introduction of nonmagnetic reagents and materials including ABEI, Co 2+ , SH-PEG, AuNP-Ab and BSA. The insert picture of Figure 3 showed that BSA/AuNP-Ab/PEG/dfCL-MB was of good dispersivity without an external magnet and it could be separated from matrix rapidly (within 10 s) under an external magnet. Therefore, the as-assembled immunosensor displayed good magnetic separation property though some nonmagnetic reagents were introduced to MB. On account of the good magnetic property, an automatic CL analyzer with a magnetic separation system (Kaeser 1000) was employed to carry out the whole testing process. First of all, to acquire the best analytical performance, the Afterwards, the selectivity of the CLIA was studied. hIgG, hIgM and other proteins including RBD and SP in SARS-CoV-2 were selected as the interferents instead of NP. As shown in the insert picture of Figure 4B , only CL signals of NP and mixture containing NP decreased obviously and the others were similar to that of blank when the interferents were 10 and 100 times as much as NP. Therefore, the immunosensor could recognize NP specifically and remain unresponsive to other proteins that might coexist in samples even when the concentration of interferents were 100-fold higher than that of NP. In other words, our label-free CLIA showed excellent selectivity to SARS-CoV-2 NP. A comparison of the proposed label-free CLIA with other previously reported methods for SARS-CoV-2 NP detection is displayed in Table 1 . We can see that both linear range and detection limit of the proposed label-free CLIA are superior to other immunoassays. Moreover, our label-free immunosensor is fabricated with only one antibody in the whole process, which make it simple, time-saving and low-cost. Besides, the proposed CLIA can be carried out by Kaeser 1000 analyzer automatically without manual operation, which will greatly reduce the infection risk of health care workers from virus-contained samples in practical applications. Additionally, the proposed label-free CLIA also possesses a competitive detection speed compared with other methods. Table 1 . A comparison of the proposed label-free CLIA with other reported methods for SARS-CoV-2 NP detection "+": need manual operation; "-": automatic method without manual operation. " ※ ": the limit of quantitation was 390 aM. Finally, the validity of the proposed label-free CLIA in complex matrix was investigated. Earlier studies showed that NP was detectable in serum samples of patients and serum NP was a sensitive and specific early diagnostic marker for COVID-19 [36] [37] [38] . Compared with swab and saliva samples, serum samples tend to have less variations and be better at eliminating sampling errors. Therefore, serum was chosen as the sample matrix. Serum samples were diluted 100 times and 20 times with 10 mM PBS without any other pretreatment. Four concentrations (1, 5, 10, 50 pg/mL) of NP were added to the diluted healthy human serum samples, respectively. Table 2 , the detected concentrations of NP were approximately consistent with the corresponding added concentration in both 100-fold and 20-fold diluted serum samples and the recovery were between 97.4% and 109.4%, demonstrating that the complex serum matrix did not have obvious influence on NP detection. Furthermore, serum samples from COVID-19 patient were also determined to estimate the practicability in real COVID-19 samples. As shown in Table 2 , the detected concentrations of NP in diluted patient serum were in agreement with previous reports [36, 39, 40] . Accordingly, the proposed label-free CLIA is of great Label-free 1 pg mL -1 to 1000 ng mL -1 0.8 pg mL -1 + >20 min Label-free 0.1 pg mL -1 to 10 000 pg mL -1 21 fg mL -1 -25 min application potential for the detection of SARS-CoV-2 NP in practical blood samples. In this work, we have successfully developed an automatic label-free CL immunoassay for SARS-CoV-2 nucleocapsid protein detection for the first time. The immunosensor was assembled by dfCL-MB and NP antibody coated AuNPs by virtue of PEG with a sulphydryl group via Au-S bond. It was found that NP could decrease the CL signal of the as-assembled immunosensor. A linear correlation between the CL intensities and the logarithm of NP concentration was obtained in the range of 0.1-10000 pg/mL. An automatic CL analyzer Kaeser 1000 was employed to carry out the detection procedure, which was a labor-saving and relatively safe way to these potential users, mainly frontline healthcare workers. The proposed label-free CLIA The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. A pneumonia outbreak associated with a new coronavirus of probable bat origin COVID-19) Dashboard Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections China Med Treatment Expert, 2020. Clinical Characteristics of Coronavirus Disease 2019 in China Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany Presumed Asymptomatic Carrier Transmission of COVID-19 Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review Antibody responses to SARS-CoV-2 in patients with COVID-19 Antigen-detection in the Diagnosis of SARS-CoV-2 Infection Using Rapid Immunoassays The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development Biochemical characterization of SARS-CoV-2 nucleocapsid protein The Impact of Mutations in SARS-CoV-2 Spike on The Genome sequence of the SARS-associated coronavirus Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Development of a SARS-CoV-2-specific biosensor for antigen detection using scFv-Fc fusion proteins SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents Foundation and Clinical Evaluation of a New Method for Detecting SARS-CoV-2 Antigen by Fluorescent Microsphere Immunochromatography Development of a Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of SARS-CoV-2 Spike Glycoprotein and Nucleoprotein A serological aptamer-assisted proximity ligation assay for COVID-19 diagnosis and seeking neutralizing aptamers Drivers of biodiagnostic development A nanozyme tag enabled chemiluminescence imaging immunoassay for multiplexed cytokine monitoring Extracellular Vesicles Enabled by CuS-Enclosed Microgels Comparison of chemiluminescence immunoassay, enzyme-linked immunosorbent assay and passive agglutination for diagnosis of Mycoplasma pneumoniae infection Performance of Treponemal Tests for the Diagnosis of Syphilis Portable Device Based on Chemiluminescence Lensless Imaging for Personalized Diagnostics through Multiplex Bioanalysis Comparison of CuO nanoparticle and CuO/MWCNT nanocomposite for amplification of chemiluminescence immunoassay for detection of the hepatitis B surface antigen in biological samples Assembly of Multifunctionalized Gold Nanoparticles with Catalytic, and Immune Activity for Label-Free Immunoassays Efficient label-free chemiluminescent immunosensor based on dual functional cupric oxide nanorods as peroxidase mimics Peroxidase Mimetics for the Design of Novel Label-Free Chemiluminescent Immunoassay Rational functional materials guided by single particle chemiluminescence imaging Highly Chemiluminescent Magnetic Beads for Label-Free Sensing of 2,4,6-Trinitrotoluene Gold Nanoparticle-Catalyzed Luminol Chemiluminescence and Its Analytical Applications Highly chemiluminescent -aminobutyl)-N-ethylisoluminol nanoluminophores for detection of heart disease biomarker copeptin based on chemiluminescence resonance energy transfer Development of a Low-Cost Cotton-Tipped Electrochemical Immunosensor for the Detection of SARS-CoV-2 N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection Nucleocapsid Protein: A Sensitivity and Specificity Early Diagnostic Marker for SARS Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease SARS-CoV-2 RapidPlex: A Graphene-Based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Microfluidic Magneto Immunosensor for Rapid, High Sensitivity Measurements of SARS-CoV-2 The support of this research by a COVID-19 special task grant supported by Chinese